BioCentury | Feb 22, 2020
Product Development
Regenerative medicine for hearing loss makes quiet progress
...the transcription factor ATOH1. Novartis gained worldwide rights to the gene therapy in 2010 from GenVec Inc....
...Koch, Executive Editor; Winnie Pong, Associate Editor, Data & Analytics Cord Blood Registry Otonomy Inc. Pipeline Therapeutics Inc. Novartis AG GenVec Inc. Frequency...
...Koch, Executive Editor; Winnie Pong, Associate Editor, Data & Analytics Cord Blood Registry Otonomy Inc. Pipeline Therapeutics Inc. Novartis AG GenVec Inc. Frequency...